GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alterity Therapeutics Ltd (NAS:ATHE) » Definitions » Price-to-Free-Cash-Flow
中文

Alterity Therapeutics (Alterity Therapeutics) Price-to-Free-Cash-Flow : N/A (As of Apr. 24, 2024)


View and export this data going back to 2002. Start your Free Trial

What is Alterity Therapeutics Price-to-Free-Cash-Flow?

As of today (2024-04-24), Alterity Therapeutics's share price is $2.33. Alterity Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $-1.36. Hence, Alterity Therapeutics's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Alterity Therapeutics's Price-to-Free-Cash-Flow or its related term are showing as below:

ATHE's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Alterity Therapeutics's Free Cash Flow per Share for the three months ended in Sep. 2023 was $0.09. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-1.36.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 10.10% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 17.40% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 12.80% per year.

During the past 13 years, Alterity Therapeutics's highest 3-Year average Free Cash Flow per Share Growth Rate was 39.90% per year. The lowest was -21.10% per year. And the median was 10.95% per year.


Alterity Therapeutics Price-to-Free-Cash-Flow Historical Data

The historical data trend for Alterity Therapeutics's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alterity Therapeutics Price-to-Free-Cash-Flow Chart

Alterity Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Alterity Therapeutics Quarterly Data
Dec17 Jun18 Dec18 Jun19 Sep19 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Alterity Therapeutics's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Alterity Therapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alterity Therapeutics's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alterity Therapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Alterity Therapeutics's Price-to-Free-Cash-Flow falls into.



Alterity Therapeutics Price-to-Free-Cash-Flow Calculation

Alterity Therapeutics's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=2.33/-1.361
=N/A

Alterity Therapeutics's Share Price of today is $2.33.
Alterity Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.36.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Alterity Therapeutics  (NAS:ATHE) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Alterity Therapeutics Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Alterity Therapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Alterity Therapeutics (Alterity Therapeutics) Business Description

Traded in Other Exchanges
Address
350 Collins Street, Level 14, Melbourne, VIC, AUS, 3000
Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.